Share This Page
Drugs in ATC Class P02C
✉ Email this page to a colleague
Subclasses in ATC: P02C - ANTINEMATODAL AGENTS
Market dynamics and patent landscape for ATC Class P02C - Antinematodal agents
What drives demand in ATC P02C (antinematodal agents)?
ATC P02C covers medicines used to treat nematode (roundworm) infections. Market demand is shaped by two lanes: (1) human therapeutics tied to morbidity control and mass drug administration, and (2) animal health tied to production economics and parasite management.
Human segment dynamics
- Program-led volume: Large-scale deworming campaigns (school-based and community-based) create recurring procurement demand for core actives.
- Resistance pressure: Continuous use of established benzimidazoles and macrocyclic lactones in some geographies drives substitution cycles and accelerates next-generation and combination strategies.
- Diagnostic-to-treatment lag: Many programs use symptom or epidemiology-based treatment rather than individualized diagnostics, sustaining demand for broad-spectrum single-dose or short-course regimens.
Animal segment dynamics
- Livestock economics: Anthelmintic choice tracks feed costs, growth performance, and milk yield impacts from helminth burdens.
- Resistance management: Rotational use and combination products are favored where resistance is documented, creating repeat demand beyond initial approvals.
- Regulatory scrutiny: Residue profiles and slaughter or milk-withdrawal windows influence formularies and tender outcomes.
Competitive structure by MOA (market reality)
P02C is dominated by a small set of pharmacological “pillars” that define prescribing behavior:
- Benzimidazoles (e.g., albendazole, mebendazole)
- Macrocyclic lactones (e.g., ivermectin, moxidectin)
- Imidazothiazoles/tetrahydropyrimidines (e.g., levamisole where applicable across regions)
- Newer nitroheterocycles and other chemical classes (smaller share, often targeted to specific indications and geographies)
This MOA concentration matters for patent strategy because follow-on opportunities typically cluster around new chemical entities (NCEs), improved formulations, and combinations.
How does the patent landscape cluster for P02C antinematodal agents?
Patent filing pattern
Across the P02C space, patent activity clusters into four families:
- Compound patents for new anthelmintic entities (often with stereochemistry and polymorph coverage).
- Formulation patents (solid dispersion, particle size reduction, taste-masking, controlled release, and pediatric-friendly dosing).
- Combination patents (fixed-dose combinations with other anthelmintics or with agents aimed at broad parasitic coverage).
- Use and method patents (dose regimens, target indications, and treatment protocols, sometimes spanning human and veterinary uses).
The portfolio architecture commonly uses claim stacking:
- Core active ingredient claims + salt/polymorph + crystalline form + formulation + process.
- Separate “therapeutic use” claims for specific indications or dose schedules.
Key enforcement realities
- Life-cycle protection is often driven by formulation and polymorph claims because many legacy actives reached early baseline expiry.
- Generics dominate where approvals and registrations are established, so innovators rely on IP that ties directly to product manufacturing and specific dosing formats.
- Combination strategies can extend commercial life even when each constituent active is off-patent, because the combination and dose regimen remain protectable.
What does the competitive patent picture look like at a high level?
Topological view of P02C patent competition
- Legacy actives: Patent portfolios are largely expired or near-expiry in many markets; competitive advantage concentrates on regulatory exclusivities, formulation IP, and brand-led market access.
- Next-generation actives: Patent families are concentrated on new chemical scaffolds and improved exposure profiles.
- Animal-health specific filings: More frequent patenting around formulation strength, bolus or pour-on formats, and resistance-management regimens.
Practical implication for investors and R&D
For P02C, the “patent shelf” is not evenly distributed. It is concentrated where:
- A company has an NCE with robust composition-of-matter coverage, and/or
- The company secures strong formulation and polymorph IP that survives generic design-arounds, and/or
- A company creates a combination with enforceable claims that is aligned to procurement preferences.
Which patents most influence market entry timing?
Entry constraints for generics
In P02C, generic entry tends to be blocked or delayed by:
- Polymorph and crystallinity control for poorly crystalline actives.
- Manufacturing process IP that constrains cost and reproducibility.
- Fixed-dose combination claims that require both actives and specific dose ratios or schedules.
Case pattern (how innovators extend commercial exclusivity)
- Innovators often file secondary patents before or around launch for:
- Crystalline forms and solvates
- Stability-enhanced formulations
- Pediatric dosing regimens
- Expanded indication use within the nematode infection field
How do market dynamics translate into pricing and volume outcomes?
Procurement and pricing
- Human deworming is usually tender- and program-driven, limiting pricing power and pushing firms to compete on supply reliability and regulatory compliance.
- Veterinary markets can sustain higher unit economics where the target species and administration format align with farmer willingness to pay and compliance.
Substitution and tender re-awards
When resistance becomes evident, procurement can shift quickly to:
- Different MOA actives,
- Combination products,
- Or products with better documented efficacy in the relevant parasite species.
Supply chain and compliance
For P02C, consistent manufacturing and regulatory submissions often drive contract awards more than marginal price differences, especially for global programs.
Where are the patent gaps likely to emerge?
Given how P02C portfolios typically mature:
- Chemical composition-of-matter space is most saturated around established scaffolds.
- Formulation and crystalline form space continues to show activity because it provides a legal pathway around off-patent actives.
- Resistance-informed combinations are likely to remain a recurring patent focus, because they map to switching behavior and regimen optimization.
The most investable “gap” profile usually looks like:
- A well-tolerated active with differentiated PK/PD or improved efficacy in resistant populations, protected by composition-of-matter plus product-form IP,
- Or an enforceable combination with a dosing scheme that procurement adopts as standard-of-care.
What are the key competitive implications for ATC P02C planning?
For R&D
- Prioritize patentable differentiation that matches real prescribing behavior:
- Dose and regimen claims that align with program protocols,
- Formulation attributes that address bioavailability, stability, and compliance,
- Combination logic that maps to procurement and resistance management.
- Design-around risk is high where differentiation is only marginal on PK exposure without enforceable formulation or method claims.
For investment and partnering
- Value the existence of “stacked” IP that survives generic formulation substitution:
- Polymorph + formulation + process + method.
- Validate market pull by tying clinical outcomes to procurement use cases:
- Specific parasite species, dosing frequency, and field efficacy.
Key Takeaways
- P02C demand is program-driven in humans and economics-driven in animals, with resistance management acting as the primary catalyst for switching.
- The patent landscape clusters around compound IP, but commercial extension more often comes from formulation, polymorph, process, and fixed-dose combination protection.
- Generic entry timing is most influenced by enforceable crystallinity/formulation/process claims and combination regimen IP, not by the core active alone.
- The most actionable opportunities typically sit in differentiated drug exposure or resistance-robust efficacy backed by stacked product-level IP that matches procurement behavior.
FAQs
1) What is the scope of ATC Class P02C?
ATC P02C is the therapeutic class for antinematodal agents, used against nematode infections in human and veterinary contexts.
2) Why do formulation patents matter disproportionately in P02C?
Many core actives in P02C have long commercial histories, so composition-of-matter protection often expires. Formulation, polymorph, and process patents can extend product-specific exclusivity and complicate generic replication.
3) What type of P02C patents most often blocks generic substitution?
Patents tied to fixed-dose combinations, crystalline forms/polymorphs, manufacturing processes, and specific dosing regimens are more likely to constrain generic design-around than broad method language.
4) What triggers procurement shifts in antinematodal programs?
Procurement typically shifts when there is evidence of reduced field efficacy driven by resistance, or when a product offers a regimen advantage that matches program logistics.
5) How should companies assess defensibility in P02C portfolios?
Assess whether the portfolio includes stacked claims across drug substance, solid state/formulation, and dosing/regimen, and whether those claims align with how products are administered in real-world procurement and use.
References
- WHO. (2024). Model Lists of Essential Medicines. World Health Organization. https://www.who.int/teams/health-product-and-policy/essential-medicines/
- ECDC. (n.d.). Helminth infections: overview and control. European Centre for Disease Prevention and Control. https://www.ecdc.europa.eu/
- WHO. (2015). Sustainable control of neglected tropical diseases: anthelminthic chemotherapy in schistosomiasis and soil-transmitted helminthiasis. World Health Organization. https://www.who.int/
- EMA. (n.d.). Medicines: Veterinary medicines and pharmacovigilance resources. European Medicines Agency. https://www.ema.europa.eu/
- FDA. (n.d.). Drugs@FDA: approvals and labeling. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/
More… ↓
